Open forum infectious diseases
T-cell Response Induced by the BNT162b2 COVID-19 Vaccine in Children.
Isabel Vogler, Stephanie Renken, Rolf Hilker, Bonny Gaby Lui, Andrew Finlayson, Alejandra Gurtman, Charulata Sabharwal, Nicholas Kitchin, Stephen Lockhart, William C Gruber, Kathrin U Jansen, Kena A Swanson, Özlem Türeci, Uğur Şahin
Published: 202510.1093/ofid/ofaf699
Abstract
Open AccessPhase 1 and Phase 2/3 trials (NCT04816643) demonstrated that the mRNA-based coronavirus disease 2019 (COVID-19) vaccine BNT162b2 is tolerable and efficacious in (5-11-year-olds) following two 10 µg doses 21 days apart, and a third 10 µg dose after 6 months. Here, we show that vaccination induces neutralizing antibodies and T-cell immunogenicity in 10-11-year-old participants.